A substantial proportion of patients enrolled on ACOSOG Z0011 received protocol-deviant radiation treatment. It is currently unknown whether these deviations involved the use of more extensive fields in patients at higher nomogram-predicted risk.
We used the M.D. Anderson (MDA) and Memorial Sloan-Kettering (MSK) nomograms to estimate risk of additional positive axillary nodes using surgical pathology information. In the control arm, we compared axillary dissection (AD) findings to nomogram-predicted estimates for validation. We used logistic regression to evaluate whether nomogram-estimated higher risk of nodal involvement was associated with high tangent (HT) or supraclavicular (SCV) radiation fields for patients with known radiation field design.
552/856 (64.5%) had complete details for the MDA nomogram. Mean MDA risk estimate in both treatment arms was 23.8%. Estimated risk for patients on the AD arm with positive nodes was 25.9%. Higher risk estimate was associated with additional positive nodes in the AD arm (OR 1.04, 95% CI 1.02–1.06, p < 0.0001). We observed significant association with higher MDA nomogram-estimated risk and SCV radiation (OR 1.07, 95% CI 1.04–1.10, p < 0.0001) but not HT (OR 0.99, 95% CI 0.96–1.02, p = 0.52) The MSK nomogram had similar associations.
MDA and MSK nomogram risk estimates were associated with lymph node risk in ACOSOG Z0011. Radiation oncologists’ use of differing radiation fields were associated with treating higher risk patients.
ClinicalTrials.gov id: NCT00003855.
This is a preview of subscription content, access via your institution.
Buy single article
Instant access to the full article PDF.
Tax calculation will be finalised during checkout.
Subscribe to journal
Immediate online access to all issues from 2019. Subscription will auto renew annually.
Tax calculation will be finalised during checkout.
Giuliano AE, Ballman KV, McCall L et al (2017) Effect of axillary dissection vs no axillary dissection on 10-year overall survival among women with invasive breast cancer and sentinel node metastasis: the ACOSOG Z0011 (Alliance) randomized clinical trial. JAMA 318:918–926
Galimberti V, Cole BF, Viale G et al (2018) Axillary dissection versus no axillary dissection in patients with breast cancer and sentinel-node micrometases (IBSCG 23-01): 10-year follow-up of a randomized, controlled phase 3 trial. Lancet Oncol 19:1385–1393
Lucci A, McCall LM, Beitsch PD et al (2007) Surgical complications associated with sentinel lymph node dissection (SLND) plus axillary lymph node dissection compared with SLND alone in the American College of Surgeons Oncology Group Trial Z0011. J Clin Oncol 25:3657–3663
Donker M, van Tienhoven G, Straver ME et al (2014) Radiotherapy or surgery of the axilla after a positive sentinel node in breast cancer (EORTC 10981-22023 AMAROS): a randomised, multicentre, open-label, phase 3 non-inferiority trial. Lancet Oncol 15:1303–1310
Rutgers EJ, Donker M, Poncet M et al (2018) Radiotherapy or surgery after a positive sentinel node in breast cancer patients: 10 year follow up results of the EORTC AMAROS trial (EORTC 10981/22023). (Abstract) Presented at the San Antonio Breast Cancer Symposium, 6 Dec 2018. San Antonio, TX.
Whelan TJ, Olivotto IA, Parulekar WR et al (2015) Regional nodal irradiation in early-stage breast cancer. New Engl J Med 373:307–316
Poortmans PM, Collette S, Kirkove C et al (2015) Internal mammary and medial supraclavicular irradiation in breast cancer. New Engl J Med 373:317–327
Jagsi R, Chadha M, Moni J, Ballman K, Laurie F, Buccholz TA, Giuliano A, Haffty BG (2014) Radiation field design in the ACOSOG Z0011 (Alliance) trial. J Clin Oncol 32:3600–3606
Mitchell JA, Cooperberg MR, Elkin EP, Lubeck DP, Mehta SS, Kane CJ, Carroll PR (2005) Ability of two pretreatment risk methods to predict prostate cancer recurrence after radical prostatectomy: data from CaPSURE. J Urol 173:1126–1131
Specht MC, Kattan MW, Gonen M, Fey J, Van Zee KJ (2005) Predicting nonsentinel node status after positive sentinel lymph biopsy for breast cancer: clinicians versus nomogram. Ann Surg Oncol 12:654–659
Ross PL, Gerigk C, Gonen M, Yossepowitch O, Cagiannos I, Sogani PC, Scardino PT, Kattan MW (2002) Comparisons of nomograms and urologists’ predictions in prostate cancer. Semin Urol Oncol 20:82–88
Giuliano AE, Hunt KK, Ballman KV et al (2011) Axillary dissection vs no axillary dissection in women with invasive breast cancer and sentinel node metastasis: a randomized clinical trial. JAMA 305:569–575
Mittendorf EA, Hunt KK, Boughey JC, Bassett R, Degnim AC, Harrell R, Yi M, Meric-Bernstam F, Ross MI, Babiera GV, Kuerer HM, Hwang RF (2012) Incorporation of sentinel lymph node metastasis size into a nomogram predicting nonsentinel lymph node involvement in breast cancer patients with a positive sentinel lymph node. Ann Surg 255:109–115
Hessman CJ, Naik AM, Kearney NM, Jensen AJ, Diggs BS, Troxell ML, Vetto JT (2011) Comparative validation of online nomograms for predicting nonsentinel lymph node status in sentinel lymph node-positive breast cancer. Arch Surg 146:1035–1040
Koca B, Kuru B, Ozen N, Yoruker S, Bek Y (2014) A breast cancer nomogram for prediction of non-sentinel node metastasis—validation of fourteen existing models. Asian Pac J Cancer Prev 15:1481–1488
Dingemans SA, de Rooij PD, van der Vuurst de Vries RM, Budel LM, Contant CM, van der Pool AE (2016) Validation of six nomograms for predicting non-sentinel lymph node metastases in a Dutch breast cancer population. Ann Surg Oncol 23:477–481
van den Hoeven I, Kuijt G, Roumen R, Voogd A, Steyeberg EW, Vergouwe Y (2015) A head to head comparison of nine tools predicting non-sentinel lymph node status in sentinel node positive breast cancer women. J Surg Oncol 112:133–138
Zhu L, Jin L, Li S, Chen K, Jia W, Shan Q, Walter S, Song E, Su F (2013) Which nomogram is best for predicting non-sentinel lymph node metastasis in breast cancer patients? A meta-analysis. Breast Cancer Res Treat 137:783–795
Schlembach PJ, Buchholz TA, Ross MI, Kirsner SM, Salas GJ, Strom EA, McNeese MD, Perkins GH, Hunt KK (2001) Relationship of sentinel and axillary level I-II lymph nodes to tangential fields used in breast irradiation. Int J Radiat Oncol Biol Phys 51:671–678
Grossmith S, Nguyen A, Hu J, Plichta JK, Nakhlis F, Cutone L, Dominici L, Golshan M, Duggan M, Carter K, Rhei E, Barbie T, Calvillo K, Nimbkar S, Bellon J, Wong J, Punglia R, Barry W, King TA (2018) Multidisciplinary management of the axilla in patients with cT1-2 N0 breast cancer undergoing primary mastectomy: results from a prospective single-institution series. Ann Surg Oncol 25:3527–3534
Mamtani A, Patil S, Stempel M, Morrow M (2017) Axillary micrometastases and isolated tumor cells are not an indication for post-mastectomy radiotherapy in Stage 1 and 2 breast cancer. Ann Surg Oncol 24:2182–2188
Haviland JS, Mannino M, Griffin C et al (2018) Late normal tissue effects in the arm and shoulder following lymphatic radiotherapy: results from the UK START (Standardisation of Breast Radiotherapy) trials. Radiother Oncol 126:155–162
Bishop JA, Sun J, Ajkay N, Sanders MA (2016) Decline in frozen section diagnosis for axillary sentinel lymph nodes as a result of the American College of Surgeons Oncology Group Z0011 trial. Arch Pathol Lab Med 140:830–835
Jorns JM, Kidwell KM (2016) Sentinel lymph node frozen-section utilization declines after publication of American College of Surgeons Oncology Group Z0011 trials results with no change in subsequent surgery for axillary lymph node dissection. Am J Clin Pathol 146:57–66
Goussous G, Jafferbhoy S, Smyth N, Hammond L, Narayanan S, Kirby RM, Soumian S (2017) Association of one-step nucleic acid amplification detected micrometastases with tumour biology and adjuvant chemotherapy. Int J Breast Cancer 2017:4971086
Piñero-Madrona A, Ruiz-Merino G, Bernet L, Miguel-Martínez B, Vicente-García F, Viguri-Díaz MA, Gímenez-Climent J (2014) Tumoral load quantification of positive sentinel lymph nodes in breast cancer to predict more than two involved nodes. Breast 23:859–864
Mattes MD, Bhatia JK, Metzger D, Ashamalla H, Katsoulakis E (2015) Breast cancer subtype as a predictor of lymph node metastasis according to the SEER registry. J Breast Cancer 18:143–148
Ugras S, Stempel M, Patil S, Morrow M (2014) Estrogen receptor, progesterone receptor, and HER2 status predict lymphovascular invasion and lymph node involvement. Ann Surg Oncol 21:3780–3786
Research reported in this publication was supported by the National Cancer Institute of the National Institutes of Health under Award Numbers U10CA180821 and U10CA180882 (to the Alliance for Clinical Trials in Oncology).The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health. https://acknowledgments.alliancefound.org.
Conflict of interest
Dr. Katz owns common stock in Dr. Reddy's Laboratories, Healthcare Services Group, Mazor Robotics, and U.S. Physical Therapy. Dr. Ballman reports grants from National Cancer Institute, during the conduct of the study; personal fees from Eli Lilly, personal fees from Janssen Pharmaceuticals, personal fees from Janssen/Johnson and Johnson, personal fees from Medtronic, personal fees from Takeda, outside the submitted work; In addition, Dr. Ballman has a patent Genomic signature of recurrence in prostate cancer with royalties paid to Mayo Clinic, and a patent Genomic signature of benefit from trastuzumab issued to Mayo Clinic. Dr. Jagsi reports stock options as compensation for her advisory board role in Equity Quotient, a company that evaluates culture in health care companies; she has received personal fees from Amgen and Vizient and grants for unrelated work from the National Institutes of Health, the Doris Duke Foundation, the Greenwall Foundation, the Komen Foundation, and Blue Cross Blue Shield of Michigan for the Michigan Radiation Oncology Quality Consortium, outside the submitted work. Dr. Giuliano reports grants and other from ACOSOG, other from Alliance, during the conduct of the study.
All procedures performed in ACOSOG Z0011 were in accordance with the ethical standards of the ACOSOG (Alliance) study group and with the 1964 Helsinki Declaration and its subsequent amendments.
Informed consent was obtained from all individual participants included in this study.
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
About this article
Cite this article
Katz, M.S., McCall, L., Ballman, K. et al. Nomogram-based estimate of axillary nodal involvement in ACOSOG Z0011 (Alliance): validation and association with radiation protocol variations. Breast Cancer Res Treat 180, 429–436 (2020). https://doi.org/10.1007/s10549-020-05555-z
- Breast cancer
- Axillary lymph node
- Sentinel lymph node
- Radiation therapy